Gatifloxacin: a review of its use in the management of bacterial infections (Q34492637)

2 August 2017

1 reference

title

Gatifloxacin: a review of its use in the management of bacterial infections (English)

1 reference

2 August 2017

1

Caroline M Perry

1 reference

2 August 2017

Douglas Ormrod

2

1 reference

2 August 2017

Miriam Hurst

series ordinal

3

1 reference

2 August 2017

Susan V Onrust

series ordinal

4

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

62

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

169-207

1 reference

Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997).

2 August 2017

cites work

1 reference

12 December 2020

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

12 December 2020

Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.

1 reference

12 December 2020

Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group

1 reference

12 December 2020

Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae

1 reference

12 December 2020

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

12 December 2020

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract

1 reference

12 December 2020

Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium

1 reference

12 December 2020

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluoroquinolones

1 reference

12 December 2020

Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.

1 reference

12 December 2020

Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.

1 reference

12 December 2020

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

12 December 2020

The future of the quinolones

1 reference

12 December 2020

Ecological effect of gatifloxacin on the normal human intestinal microflora

1 reference

12 December 2020

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

1 reference

12 December 2020

Effect of quinolones on intestinal ecology

1 reference

12 December 2020

What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

1 reference

12 December 2020

Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics

1 reference

12 December 2020

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States

1 reference

12 December 2020

The new fluoroquinolones: A critical review

1 reference

12 December 2020

Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study

1 reference

12 December 2020

Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections

1 reference

12 December 2020

In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria

1 reference

12 December 2020

Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

1 reference

12 December 2020

Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint

1 reference

12 December 2020

In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp

1 reference

12 December 2020

Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.

1 reference

12 December 2020

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

12 December 2020

Expanded activity and utility of the new fluoroquinolones: a review

1 reference

12 December 2020

In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods

1 reference

12 December 2020

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

12 December 2020

In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Su

1 reference

12 December 2020

Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial

1 reference

12 December 2020

Managing antibiotic resistance

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

12 December 2020

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

12 December 2020

Quinolone activity against anaerobes

1 reference

12 December 2020

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

12 December 2020

1 reference

12 December 2020

Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study

1 reference

12 December 2020

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

12 December 2020

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract

1 reference

12 December 2020

Gatifloxacin-induced QTc prolongation and ventricular tachycardia

1 reference

12 December 2020

Activity of quinolones against Chlamydia pneumoniae

1 reference

12 December 2020

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program

1 reference

12 December 2020

Age and gender effects on the pharmacokinetics of gatifloxacin.

1 reference

12 December 2020

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America

1 reference

12 December 2020

Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline.

1 reference

12 December 2020

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998

1 reference

12 December 2020

Efficacy of gatifloxacin in experimental Escherichia coli meningitis

1 reference

12 December 2020

Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

1 reference

12 December 2020

Mechanisms of fluoroquinolone resistance

1 reference

12 December 2020

Mechanisms of fluoroquinolone resistance: an update 1994-1998.

1 reference

12 December 2020

Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997

1 reference

12 December 2020

Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.

1 reference

12 December 2020

Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers

1 reference

12 December 2020

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

1 reference

12 December 2020

Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.

1 reference

12 December 2020

A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers

1 reference

12 December 2020

Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers

1 reference

12 December 2020

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

1 reference

12 December 2020

Quinolones: which generation for which microbe?

1 reference

12 December 2020

Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.

1 reference

12 December 2020

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance

1 reference

12 December 2020

A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose

1 reference

12 December 2020

10.2165/00003495-200262010-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1019792815

0 references

1 reference